Clinical and neurobiological characterisation of muscarinic receptor-deficit schizophrenia (MRDS)

Withdrawn

• Conditions: MRDS; psychosis; 10039628

• Registration Number: NL-OMON38703
• Lead Sponsor: niversiteit Maastricht

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 29 April 2024

Recruitment & Eligibility

• Status: Withdrawn
• Sex: Not specified
• Target Recruitment: 90

Inclusion Criteria

-Patients with first-episode psychosis as defined by the standardised criteria of the CASH
-Antipsychotic naïve
-Duration of untreated psychosis no more than 1 year.
-16 years and older

Exclusion Criteria

-Use of antipsychotics or anticholinergics
-Contraindications for MRI
-Severe neurological, endocrine or psychiatric disorders
-Pregnancy
-Current use of recreational drugs; participants must be abstinent of recreational drugs such as cannabis at least 4 weaks prior to participation.
-Tardive dyskinesia

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>-M1 receptor binding: ROI*s will be the hippocampus, striatum and dorsolateral<br /><br>prefrontal cortex.<br /><br><br /><br>-BOLD signal activation during cognitive tasks PAL (40) and ER -40 (62) under<br /><br>cholinergic challenge and in placebo. (ROI*s DLPFC, hippocampus, and striatum).<br /><br><br /><br>-Neuropsychological tests: CANTAB battery for schizophrenia.</p><br>

Secondary Outcome Measures

Name	Time	Method
<p>-DTI<br /><br>-RSfMRI<br /><br>-MRS placebo & biperideen<br /><br>-(Epi)genetics</p><br>